PINE BLUFF, Ark., May 25 /PRNewswire/ -- Jefferson Regional Medical Center (JRMC), a not-for-profit public 470 bed hospital serving South Arkansas, has recently standardized on Masimo SET (Signal Extraction Technology) oximetry hospital-wide. JRMC cited improved monitoring during high motion and poor perfusion, and overall cost-savings, as key reasons for their Masimo conversion.
Dr. Ferdinand K. Samuel, department of Anesthesiology, said, "We decided to use Masimo because our clinicians needed better pulse oximetry for patients with motion and low perfusion. We have been live with Masimo for two months and are happy with its performance. The sensitivity with Masimo is better and the reading is truer."
Joe E. Kiani, Chief Executive Officer of Masimo stated, "We are proud to help JRMC deliver world-class care to the patients of South Arkansas. From geriatrics to radiology, we believe Masimo's breakthrough read-through motion and low perfusion pulse oximetry will contribute to even greater patient outcomes at Jefferson Regional."
About Jefferson Regional Medical Center
Licensed for 471 beds, JRMC is the fourth largest hospital in the state of Arkansas. It serves 280,000 residents of 11 South Arkansas counties, and is supported by a medical staff of approximately 150 physicians representing 30 different specialties.
About Masimo
Masimo, founded in 1989, is the innovator and leader of read-through motion and low perfusion pulse oximetry. Masimo develops, licenses, and markets advanced medical signal processing technologies and products for the non-invasive monitoring of vital signs. Masimo Signal Extraction Technology, or Masimo SET, represents the standard of care for pulse oximeters. Over 90 clinical studies support the conclusion that Masimo SET is the most effective pulse oximeter in the world. Masimo is headquartered in Irvine, California. Additional information about Masimo and its products can be found at http://www.masimo.com/.
Masimo is currently offering a $250,000 guarantee to hospitals seeking an upgrade to next generation pulse oximetry. If Masimo does not outperform Nellcor in an objective clinical trial, Masimo will pay that hospital $250,000 towards the purchase of Nellcor oximetry. Contact Masimo for more details.
MasimoCONTACT: Brad Langdale of Masimo Corporation, 1-949-297-7009,blangdale@masimo.com
Web site: http://www.masimo.com/